Sign in
4

Changes in Ownership

BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-044861

CEO and President sold 5,268 shares at an average $2.62 ($13,823)

  • CEO and President acquired 16,610 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Mehta Vimal · CEO and President

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2024-03-14 Exercise or conversion : show line 1 in the form 10b5-1 +2,610 34,832 D
2024-03-15 Exercise or conversion : show line 2 in the form 10b5-1 +14,000 48,832 D
2024-04-04 Sale : show line 3 in the form 10b5-1 −829 $2.62 $2,172 48,003 D
2024-04-04 Sale : show line 4 in the form 10b5-1 −4,439 $2.62 $11,651 43,564 D
Open-market sales · 5,268 sh · avg $2.62 · $13,823

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2024-03-14 Exercise or conversion : show line 5 in the form 10b5-1 Restricted Stock Units −2,610 20,875 D
2024-03-15 Exercise or conversion : show line 6 in the form 10b5-1 Restricted Stock Units −14,000 42,000 D
Loading xslF345X05/tm2411220-5_4seq1.xml…